Specialty: Hematology and Medical Oncology

Background:
Dr. Jarred Reed is a board-certified hematologist and oncologist. He treats all patients with solid tumors and hematologic conditions, with a particular interest in genitourinary malignancies including kidney, prostate, and bladder cancer. He is also active in projects focused on cancer genetics, medical education, and improved access to care for cancer patients.

Dr. Reed received his undergraduate degree from Georgetown University with a major in Biochemistry. He received his medical degree from Duke University School of Medicine. He completed Internal Medicine residency at UCLA Ronald Reagan Medical Center, where he joined the Internal Medicine faculty for one year before completing fellowship training in Hematology and Medical Oncology at Olive View-UCLA Medical Center. After completing fellowship Dr. Reed joined the faculty at Olive View-UCLA Medical Center, which he viewed as an ideal environment to continue to care for the underserved population of Los Angeles County and participate in the training of future Hematologist/Oncologists.

Research Interests:
Genitourinary Malignancies
Access to Care

Education:
M.D., Duke University School of Medicine, 2013
Internal Medicine Residency, UCLA Ronald Reagan Medical Center, 2013-2016
Hematology and Medical Oncology Fellowship, Olive View-UCLA Medical Center, 2017-2020

Committees & Administrative Duties:
Institutional Review Board, Olive View-UCLA Medical Center
DHS Genetics Workgroup
Medical Executive Committee
Clinical Competency Committee, Fellowship in Hematology and Medical Oncology

Recent Publications & Projects:
Adashek JJ, Reed JP, Tandon A, et al. Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?. Clin Genitourin Cancer. 2020; Dec; 18(6):425-428

Reed JP, Chung J, Banerjee N. A Case of Cobalamin Deficiency and Macrocytic Anemia Secondary to Sunitinib. Cureus. https://doi.org/10/7759/cureus/4310. 2019.

Reed JP, Posadas EM, Figlin RA. Brain Metastases in Renal Cell Carcinoma: Immunotherapy Responsiveness Is Multifactorial and Heterogeneous. J Clin Oncol. 2019;37(23):1987-1989.
Reed JP, Posadas EM, Figlin RA. Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma. Expert Rev Anticancer Ther. 2019;19(3):259-271.

Reed JP, Devkota S, Figlin RA. Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer. Ann Transl Med. 2019;7(Suppl 8):S309.

Pennington JD, Eilber FC, Eilber FR, Singh AS, Reed, JP, … Kamrava M. (2018). Long-term Outcomes with Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas. American Journal of Clinical Oncology, 41(12), 1154–1161.

Interests:
Family time, sports